Literature DB >> 18773988

Incidence of coronary stent thrombosis based on academic research consortium definitions.

Robert J Applegate1, Matthew T Sacrinty, William C Little, Renato M Santos, Sanjay K Gandhi, Michael A Kutcher.   

Abstract

Stent thrombosis occurs infrequently after drug-eluting stent (DES) placement, but concerns have surfaced that identification of stent thrombosis based solely on angiography may underestimate the true incidence of this complication. The purpose of this study was to compare rates of stent thrombosis using Academic Research Consortium (ARC) definitions. From April 2002 to February 2005, bare-metal stents (BMSs) and DESs were placed at Wake Forest University Baptist Medical Center. Rates of ARC definite, probable, and possible stent thrombosis were evaluated. Overall, definite stent thrombosis occurred in 1.4% of BMSs and 1.1% of DESs (p = 0.47); probable stent thrombosis, in 1.0% of BMSs and 0.9% of DESs (p = 0.81); definite plus probable stent thrombosis, in 2.3% of BMSs and 1.9% of DESs (p = 0.48); and possible stent thrombosis, in 6.8% of BMSs and 3.5% of DESs (p <0.001). Rates of definite late (31 days to 1 year) and very late (>1 year) stent thrombosis were 0.9% for BMSs and 0.06% for DESs (p <0.001) and 0.16% for BMSs and 0.56% for DESs, respectively (p = 0.13). Rates of definite plus probable and late and very late stent thrombosis were 1.1% for BMSs and 0.19% for DESs (p <0.001) and 0.40% for BMSs and 0.68% for DESs, respectively (p = 0.31). Rates of possible stent thrombosis increased significantly for each thrombosis interval. In conclusion, rates of stent thrombosis using the proposed ARC definition differed by stent type, definition of stent thrombosis, and thrombosis interval. Use of the ARC probable stent thrombosis paralleled rates of definite stent thrombosis alone, but partially masked the occurrence of late (>1 year) stent thrombosis in DESs compared with BMSs.

Entities:  

Mesh:

Year:  2008        PMID: 18773988     DOI: 10.1016/j.amjcard.2008.04.050

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.

Authors:  J P Lewis; A S Fisch; K Ryan; J R O'Connell; Q Gibson; B D Mitchell; H Shen; K Tanner; R B Horenstein; R Pakzy; U S Tantry; K P Bliden; P A Gurbel; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-08-31       Impact factor: 6.875

2.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

3.  Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis.

Authors:  Qiang Wang; Keping Yang
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

4.  Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020.

Authors:  Jing Nan; Shuai Meng; Hongyu Hu; Ruofei Jia; Wei Chen; Qun Li; Tong Zhang; Ke Song; Yang Wang; Zening Jin
Journal:  Med Sci Monit       Date:  2020-09-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.